Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
ClouDr Group Limited ( (HK:9955) ) has provided an update.
ClouDr Group Limited has warned that its consolidated net loss for the year ended December 31, 2025 is expected to widen to between RMB880 million and RMB980 million, compared with a RMB491.4 million loss a year earlier. The deterioration is mainly attributed to significant impairment losses from the disposal of certain subsidiaries and a one-off specific provision linked to a business whose counterparty faces major legal proceedings.
Despite the larger accounting loss, the Group’s operating cash flow is expected to improve markedly, shifting from a net cash outflow of RMB148.4 million in 2024 to a net cash inflow of between RMB50 million and RMB80 million in 2025. Management attributes this improvement to its strategic divestment of low-margin medical supplies operations and its pivot to AI-focused, higher-efficiency P2M activities, signaling a bid to strengthen underlying cash generation even as restructuring costs weigh on reported earnings.
The most recent analyst rating on (HK:9955) stock is a Sell with a HK$0.86 price target. To see the full list of analyst forecasts on ClouDr Group Limited stock, see the HK:9955 Stock Forecast page.
More about ClouDr Group Limited
ClouDr Group Limited is a Hong Kong-listed company incorporated in the Cayman Islands that is undergoing a strategic transformation of its business model. The Group is divesting low-margin medical supplies sales and shifting its focus toward core artificial intelligence capabilities and an AI-driven P2M business aimed at higher operating efficiency and stronger cash generation.
Average Trading Volume: 782,608
Technical Sentiment Signal: Sell
Current Market Cap: HK$559.8M
Learn more about 9955 stock on TipRanks’ Stock Analysis page.